Original ArticleConformation-dependent binding and tumor-targeted delivery of siRNA by a designed TRBP2: Affibody fusion protein
Graphical Abstract
Recombinant protein with HER-2 targeting and siRNA binding motifs for efficient in vivo siRNA delivery to tumors
Section snippets
Background
RNA interference holds a great potential in cancer therapy due to its high specificity and ability to efficiently silence a large number of different genes involving a number of distinct cellular pathways.1, 2 This is particularly important for a disease as complex as cancer. However, as in other drug targeting therapies, the major challenge for therapeutic use of siRNA is the need for devising safe, stable and effective carriers capable of delivering low doses of siRNA into the cytoplasm. A
Cell culture
SK-OV-3, MDA-MB-231 and MDA-MB-453 were obtained Medina-Lai Kauwe, University of Southern California Keck School of Medicine, CA. Other cells were obtained from lab stocks. These were maintained in a Dulbecco's Modified Eagle Medium (DMEM): Nutrient Mixture F-12 (DMEM/F-12, Life Technologies) with 10% fetal bovine serum (Life Technologies).
Flow cytometry and confocal microscopy
Cells grown in tissue culture flasks were trypsinized and pelleted. Approximately 50,000 cells were incubated with 40 pmol of FAM-labeled siRNA either alone
Design, purification and structural properties of TRAF
TRAF protein was designed by fusing second domain of TRBP2 (due to its higher affinity) to the DNA sequence of ZHER-2 affibody molecule. To aid proper folding, five glycine codons were inserted between the two domains. During purification, we noticed bacterial RNA associated with TRAF (data not shown) that was removed by adding urea in the lysis buffer. Additionally, 0.1% Triton-X114 was used to remove bacterial endotoxins.29 The purified protein was characterized by SDS-PAGE and mass
Discussion
Efficient delivery of siRNA is a challenge for realizing its gene silencing potential as these approaches involve protection of siRNA from degradation and cellular uptake followed by timely release inside the cell. Besides, it is important for the delivery vehicle to be stable and free from toxicity. Natural or biosimilar entities have shown promising results in delivering siRNA compared to vehicles that are complex or prepared with synthetic materials.1, 3, 5 Moreover, nature has evolved a
Design of TRAF
Cationic polymers and cationic amphiphile structures are considered as gold standard in carrying nucleic acids including siRNA efficiently into the cells in vitro.23 However, electrostatic interaction between siRNA and cationic polymers leads to the formation of heterogeneous aggregates that are susceptible to adhesion of serum proteins, resulting in rapid extravasation from the blood.1, 3 Additionally, cationic polymers such as polyarginine, protamine sulfate and several cell penetrating
Tracking of TRAF:siRNA complexes in cells and in mice
One of the crucial steps in siRNA delivery is its availability to the RISC complex for mediating knockdown of desired genes. Majority of the complexes find their way into the endosomes after taking different entry routes. As endosomes face multiple fates like retrograde or lysosomal route, it is important that siRNA is released from the endosomes into the cytoplasm.46 Recently it has been observed that only 1-3% of the total siRNA internalized is released into the cytoplasm during early
Acknowledgment
The authors acknowledge E. Nathan for helping in developing tumor xenografts, Avinash for tissue cryosectioning, N.R. Chakravarthi for technical assistance in animal live imaging and Nandini for assisting in confocal microscopy.
References (51)
- et al.
Action and reaction: the biological response to siRNA and its delivery vehicles
Mol Ther
(2012) - et al.
Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras
Mol Ther
(2013) - et al.
Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes
Nanomedicine
(2011) - et al.
Gene silencing mediated by siRNA-binding fusion proteins is attenuated by double-stranded RNA-binding domain structure
Mol Ther Nucleic Acids
(2012) - et al.
Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA
Mol Ther Nucleic Acids
(2012) - et al.
Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies
Mol Ther Nucleic Acids
(2012) - et al.
Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid
Biomaterials
(2011) - et al.
dsRNA binding properties of RDE-4 and TRBP reflect their distinct roles in RNAi
J Mol Biol
(2008) - et al.
Single step protocol to purify recombinant proteins with low endotoxin contents
Protein Expr Purif
(2006) - et al.
At the acidic edge: emerging functions for lysosomal membrane proteins
Trends Cell Biol
(2003)
Fluorescence imaging in vivo: recent advances
Curr Opin Biotechnol
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Neoplasia
An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection
Biomaterials
Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate
Biomaterials
Strategies for silencing human disease using RNA interference
Nat Rev Genet
Gene therapy progress and prospects: RNA aptamers
Gene Ther
Lipidic systems for in vivo siRNA delivery
AAPS J
The future of peptide-based drugs
Chem Biol Drug Des
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides
Ther Deliv
Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment
Bioconjug Chem
Structural basis for high-affinity HER2 receptor binding by an engineered protein
Proc Natl Acad Sci U S A
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Nat Biotechnol
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1
Proc Natl Acad Sci U S A
Transvascular delivery of small interfering RNA to the central nervous system
Nature
Complement activation by interaction of polyanions and polycations
Immunology
Cited by (13)
RNA-binding proteins in breast cancer: Biological implications and therapeutic opportunities
2024, Critical Reviews in Oncology/HematologyProtein-based delivery systems for RNA delivery
2023, Journal of Controlled ReleaseToward the therapeutic application of small interfering RNA bioconjugates in the central nervous system
2020, Handbook of Innovations in Central Nervous System Regenerative MedicineAffibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer
2018, International Journal of Biological MacromoleculesCitation Excerpt :The hybrid TRAF complex effectively binds with the siRNA and selectively transport it into HER2 overexpressing cancer cells. Administration of siRNA by hybrid TRAF into tissues resulted in significant silencing of chosen genes involved in cell proliferation viz. AURKB and ErbB2 and a good candidate for the EbB2 overexpressed carcinoma [111]. Zhang et al., prepared a DNA affibody complex loaded with ∼53 molecules of DOX.
Affibody Molecules in Biotechnological and Medical Applications
2017, Trends in BiotechnologyFunctional peptides for siRNA delivery
2017, Advanced Drug Delivery Reviews
We gratefully acknowledge financial support from CSIR (BSC0112). GHD is also grateful to CSIR for a Senior Research Fellowship.